{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:27Z","timestamp":1790402307404,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["DK129664"],"award-info":[{"award-number":["DK129664"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI","award":["CA280749-01"],"award-info":[{"award-number":["CA280749-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02608-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T03:19:03Z","timestamp":1747019943000},"page":"2001-2012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7619-8701","authenticated-orcid":false,"given":"Sara S.","family":"Hammerstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1590-2547","authenticated-orcid":false,"given":"Yaron","family":"Tomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-9132","authenticated-orcid":false,"given":"Mihaela","family":"Stefan-Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2608_CR1","volume-title":"Collected studies on immunity","author":"P Ehrlich","year":"1906","unstructured":"Ehrlich P (1906) Collected studies on immunity. J Wiley & Sons, New York"},{"issue":"12","key":"2608_CR2","first-page":"84","volume":"8","author":"II Phase","year":"1994","unstructured":"Phase II (1994) Results using a new antibody in the treatment of lymphoma. Oncol (Williston Park) 8(12):84","journal-title":"Oncol (Williston Park)"},{"issue":"2","key":"2608_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1042\/bst0250705","volume":"25","author":"DR Anderson","year":"1997","unstructured":"Anderson DR, Grillo-L\u00f3pez A, Varns C, Chambers KS, Hanna N (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma. Biochem Soc Trans 25(2):705\u2013708. https:\/\/doi.org\/10.1042\/bst0250705","journal-title":"Biochem Soc Trans"},{"key":"2608_CR4","doi-asserted-by":"publisher","unstructured":"Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P et al (2021) The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer.158:217\u2013\u200924. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.048","DOI":"10.1016\/j.ejca.2021.08.048"},{"issue":"26","key":"2608_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"issue":"1","key":"2608_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1212631","volume":"94","author":"MK Callahan","year":"2013","unstructured":"Callahan MK, Wolchok JD (2013) At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94(1):41\u201353. https:\/\/doi.org\/10.1189\/jlb.1212631","journal-title":"J Leukoc Biol"},{"issue":"5","key":"2608_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","volume":"7","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely JR Jr., Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M et al (2021) Chronic Immune-Related adverse events following adjuvant Anti-PD-1 therapy for High-risk resected melanoma. JAMA Oncol 7(5):744\u2013748. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0051","journal-title":"JAMA Oncol"},{"key":"2608_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","volume":"119","author":"B El Osta","year":"2017","unstructured":"El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC (2017) Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2608_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and Meta-analysis. JAMA Oncol 4(2):173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"2608_CR10","unstructured":"Elshimy GRR, Akturk HK et al Immune Checkpoint Inhibitors Related Endocrine Adverse Events. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.: [Updated 2022 Jan 21]"},{"key":"2608_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M et al (2017) Endocrine-related adverse events associated with immune checkpoint Blockade and expert insights on their management. Cancer Treat Rev 58:70\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2608_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (2019) A systematic review and Meta-Analysis of Endocrine-Related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(3):145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"issue":"4","key":"2608_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy - immune checkpoint Blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2608_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/erc-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371\u2013381. https:\/\/doi.org\/10.1530\/erc-13-0499","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2608_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/1744666x.2021.1974297","volume":"17","author":"F Frasca","year":"2021","unstructured":"Frasca F, Piticchio T, Le Moli R, Malaguarnera R, Campenn\u00ec A, Cannav\u00f2 S et al (2021) Recent insights into the pathogenesis of autoimmune hypophysitis. Expert Rev Clin Immunol 17(11):1175\u20131185. https:\/\/doi.org\/10.1080\/1744666x.2021.1974297","journal-title":"Expert Rev Clin Immunol"},{"issue":"230","key":"2608_CR16","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6(230):230ra45. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"issue":"6","key":"2608_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.seminoncol.2023.11.003","volume":"50","author":"S Martella","year":"2023","unstructured":"Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A et al (2023) Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol 50(6):144\u2013148. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.11.003","journal-title":"Semin Oncol"},{"issue":"1","key":"2608_CR18","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","volume":"7","author":"A Kotwal","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7(1):e000591. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2608_CR19","doi-asserted-by":"publisher","first-page":"798517","DOI":"10.3389\/fonc.2022.798517","volume":"12","author":"A Barnabei","year":"2022","unstructured":"Barnabei A, Strigari L, Corsello A, Paragliola RM, Falzone L, Salvatori R et al (2022) Immune checkpoint Inhibitor-Induced central diabetes insipidus: looking for the needle in the haystack or a very rare Side-Effect to promptly diagnose?? Front Oncol 12:798517. https:\/\/doi.org\/10.3389\/fonc.2022.798517","journal-title":"Front Oncol"},{"key":"2608_CR20","doi-asserted-by":"publisher","unstructured":"Shi Y, Shen M, Zheng X, Chen Y, Zhao R, Gu Y et al (2020) ICPis-Induced autoimmune polyendocrine syndrome type 2: A review of the literature and a protocol for optimal management. J Clin Endocrinol Metab 105(12). https:\/\/doi.org\/10.1210\/clinem\/dgaa553","DOI":"10.1210\/clinem\/dgaa553"},{"issue":"2","key":"2608_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2018-01151","volume":"104","author":"P Piranavan","year":"2019","unstructured":"Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N (2019) Immune checkpoint Inhibitor-Induced hypoparathyroidism associated with Calcium-Sensing Receptor-Activating autoantibodies. J Clin Endocrinol Metab 104(2):550\u2013556. https:\/\/doi.org\/10.1210\/jc.2018-01151","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2608_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","volume":"7","author":"B Trinh","year":"2019","unstructured":"Trinh B, Sanchez GO, Herzig P, L\u00e4ubli H (2019) Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint Blockade for melanoma. J Immunother Cancer 7(1):52. https:\/\/doi.org\/10.1186\/s40425-019-0528-x","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2608_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","volume":"4","author":"OM El Kawkgi","year":"2020","unstructured":"El Kawkgi OM, Li D, Kotwal A, Wermers RA (2020) Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes 4(6):821\u2013825. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.07.006","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"3","key":"2608_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","volume":"69","author":"X Bai","year":"2020","unstructured":"Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y et al (2020) Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database. VigiBase Endocr 69(3):670\u2013681. https:\/\/doi.org\/10.1007\/s12020-020-02355-9","journal-title":"VigiBase Endocr"},{"issue":"5","key":"2608_CR25","doi-asserted-by":"publisher","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","volume":"107","author":"CA Muir","year":"2022","unstructured":"Muir CA, Wood CCG, Clifton-Bligh RJ, Long GV, Scolyer RA, Carlino MS et al (2022) Association of antithyroid antibodies in checkpoint Inhibitor-Associated thyroid Immune-Related adverse events. J Clin Endocrinol Metab 107(5):e1843\u2013e9. https:\/\/doi.org\/10.1210\/clinem\/dgac059","journal-title":"J Clin Endocrinol Metab"},{"key":"2608_CR26","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ (2022) Immune related adverse events of the Thyroid - A narrative review. Front Endocrinol (Lausanne) 13:886930. https:\/\/doi.org\/10.3389\/fendo.2022.886930","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2608_CR27","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2020.0032","volume":"30","author":"CA Muir","year":"2020","unstructured":"Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM (2020) Thyroid toxicity following immune checkpoint inhibitor treatment in advanced Cancer. Thyroid 30(10):1458\u20131469. https:\/\/doi.org\/10.1089\/thy.2020.0032","journal-title":"Thyroid"},{"issue":"8","key":"2608_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00262-024-03733-2","volume":"73","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K et al (2024) Combined use of tyrosine kinase inhibitors with PD-(L)1 Blockade increased the risk of thyroid dysfunction in PD-(L)1 Blockade: a prospective study. Cancer Immunol Immunother 73(8):146. https:\/\/doi.org\/10.1007\/s00262-024-03733-2","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2608_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/thy.2023.0542","volume":"34","author":"K Tsai","year":"2024","unstructured":"Tsai K, Ma H, Liang TZ, Xing Y, Chung S, Dorff T et al (2024) The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function. Thyroid 34(2):158\u2013166. https:\/\/doi.org\/10.1089\/thy.2023.0542","journal-title":"Thyroid"},{"key":"2608_CR30","doi-asserted-by":"publisher","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR et al (2018) Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid.28(10):1243-51. https:\/\/doi.org\/10.1089\/thy.2018.0116","DOI":"10.1089\/thy.2018.0116"},{"issue":"3","key":"2608_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000464285","volume":"6","author":"EH Gan","year":"2017","unstructured":"Gan EH, Mitchell AL, Plummer R, Pearce S, Perros P (2017) Tremelimumab-Induced graves hyperthyroidism. Eur Thyroid J 6(3):167\u2013170. https:\/\/doi.org\/10.1159\/000464285","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2608_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/eje-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164(2):303\u2013307. https:\/\/doi.org\/10.1530\/eje-10-0833","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2608_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.18240\/ijo.2022.04.19","volume":"15","author":"YW Zhou","year":"2022","unstructured":"Zhou YW, Xu Q, Wang Y, Xia RL, Liu JY, Ma XL (2022) Immune checkpoint inhibitor-associated ophthalmic adverse events: current Understanding of its mechanisms, diagnosis, and management. Int J Ophthalmol 15(4):646\u2013656. https:\/\/doi.org\/10.18240\/ijo.2022.04.19","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"2608_CR34","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 27(4):e87\u2013e88. https:\/\/doi.org\/10.1097\/IOP.0b013e3181ef72a1","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"2608_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000485742","volume":"7","author":"P Campredon","year":"2018","unstructured":"Campredon P, Imbert P, Mouly C, Grunenwald S, Mazi\u00e8res J, Caron P (2018) Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Eur Thyroid J 7(2):84\u201387. https:\/\/doi.org\/10.1159\/000485742","journal-title":"Eur Thyroid J"},{"key":"2608_CR36","doi-asserted-by":"publisher","unstructured":"Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E et al (2021) Graves\u2019 Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers (Basel) 13(8). https:\/\/doi.org\/10.3390\/cancers13081944","DOI":"10.3390\/cancers13081944"},{"issue":"1","key":"2608_CR37","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","volume":"11","author":"D Michailidou","year":"2021","unstructured":"Michailidou D, Khaki AR, Morelli MP, Diamantopoulos L, Singh N, Grivas P (2021) Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep 11(1):9029. https:\/\/doi.org\/10.1038\/s41598-021-88307-3","journal-title":"Sci Rep"},{"issue":"6","key":"2608_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","volume":"68","author":"KL Kehl","year":"2019","unstructured":"Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68(6):917\u2013926. https:\/\/doi.org\/10.1007\/s00262-019-02321-z","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2608_CR39","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M et al (2019) Clinical outcomes of patients with advanced Cancer and Pre-Existing autoimmune diseases treated with Anti-Programmed Death-1 immunotherapy: A Real-World transverse study. Oncologist 24(6):e327\u2013e37. https:\/\/doi.org\/10.1634\/theoncologist.2018-0618","journal-title":"Oncologist"},{"issue":"6","key":"2608_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","volume":"122","author":"N Okada","year":"2020","unstructured":"Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E et al (2020) Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 122(6):771\u2013777. https:\/\/doi.org\/10.1038\/s41416-020-0736-7","journal-title":"Br J Cancer"},{"issue":"3","key":"2608_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","volume":"5","author":"Y Toi","year":"2019","unstructured":"Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T et al (2019) Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced Non-Small cell lung Cancer. JAMA Oncol 5(3):376\u2013383. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5860","journal-title":"JAMA Oncol"},{"issue":"3","key":"2608_CR42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint Blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"issue":"8","key":"2608_CR43","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","volume":"44","author":"L Brilli","year":"2021","unstructured":"Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabr\u00f2 L et al (2021) Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 44(8):1719\u20131726. https:\/\/doi.org\/10.1007\/s40618-020-01480-6","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2608_CR44","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","volume":"46","author":"RM Ruggeri","year":"2023","unstructured":"Ruggeri RM, Spagnolo CC, Alibrandi A, Silvestris N, Cannav\u00f2 S, Santarpia M (2023) Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center. J Endocrinol Invest 46(11):2399\u20132409. https:\/\/doi.org\/10.1007\/s40618-023-02096-2","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2608_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","volume":"43","author":"EM Presotto","year":"2020","unstructured":"Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N et al (2020) Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest 43(3):337\u2013345. https:\/\/doi.org\/10.1007\/s40618-019-01112-8","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2608_CR46","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","volume":"44","author":"C Luongo","year":"2021","unstructured":"Luongo C, Morra R, Gambale C, Porcelli T, Sessa F, Matano E et al (2021) Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. J Endocrinol Invest 44(9):1927\u20131933. https:\/\/doi.org\/10.1007\/s40618-021-01508-5","journal-title":"J Endocrinol Invest"},{"key":"2608_CR47","doi-asserted-by":"publisher","first-page":"1169173","DOI":"10.3389\/fendo.2023.1169173","volume":"14","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Manavalan A, Stefan-Lifshitz M, Schechter C, Maity A, Tomer Y (2023) Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis May be associated with improved survival: results of an exploratory study. Front Endocrinol (Lausanne) 14:1169173. https:\/\/doi.org\/10.3389\/fendo.2023.1169173","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2608_CR48","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","volume":"21","author":"E Gonz\u00e1lez-Rodr\u00edguez","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21(7):804\u2013816. https:\/\/doi.org\/10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"},{"issue":"1","key":"2608_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2478\/jtim-2022-0009","volume":"10","author":"D Lu","year":"2022","unstructured":"Lu D, Gao Y (2022) Immune checkpoint Inhibitor-related endocrinopathies. J Transl Int Med 10(1):9\u201314. https:\/\/doi.org\/10.2478\/jtim-2022-0009","journal-title":"J Transl Int Med"},{"issue":"8","key":"2608_CR50","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","volume":"19","author":"P Triggianese","year":"2020","unstructured":"Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R et al (2020) Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun Rev 19(8):102590. https:\/\/doi.org\/10.1016\/j.autrev.2020.102590","journal-title":"Autoimmun Rev"},{"key":"2608_CR51","doi-asserted-by":"publisher","unstructured":"Pollack R, Ashash A, Cahn A, Rottenberg Y, Stern H, Dresner-Pollak R (2020) Immune checkpoint Inhibitor-induced thyroid dysfunction is associated with higher body mass index. J Clin Endocrinol Metab 105(10). https:\/\/doi.org\/10.1210\/clinem\/dgaa458","DOI":"10.1210\/clinem\/dgaa458"},{"key":"2608_CR52","doi-asserted-by":"publisher","unstructured":"Park H, Hata A, Hatabu H, Ricciuti B, Awad M, Nishino M (2023) Immune-Related thyroiditis in patients with advanced lung Cancer treated with immune checkpoint inhibitors: imaging features and clinical implications. Cancers (Basel) 15(3). https:\/\/doi.org\/10.3390\/cancers15030649","DOI":"10.3390\/cancers15030649"},{"issue":"36","key":"2608_CR53","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"2608_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2608_CR55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000501824","volume":"8","author":"A Brancatella","year":"2019","unstructured":"Brancatella A, Viola N, Brogioni S, Montanelli L, Sardella C, Vitti P et al (2019) Graves\u2019 disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur Thyroid J 8(4):192\u2013195. https:\/\/doi.org\/10.1159\/000501824","journal-title":"Eur Thyroid J"},{"issue":"6","key":"2608_CR56","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","volume":"108","author":"JJ Wright","year":"2023","unstructured":"Wright JJ, Johnson DB (2023) Approach to the patient with immune checkpoint Inhibitor-Associated endocrine dysfunction. J Clin Endocrinol Metab 108(6):1514\u20131525. https:\/\/doi.org\/10.1210\/clinem\/dgac689","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2608_CR57","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918. https:\/\/doi.org\/10.1016\/s1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"issue":"9","key":"2608_CR58","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS et al (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106(9):e3704\u2013e13. https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2608_CR59","doi-asserted-by":"publisher","first-page":"R196","DOI":"10.1530\/EC-18-0079","volume":"7","author":"J Jaafar","year":"2018","unstructured":"Jaafar J, Fernandez E, Alwan H, Philippe J (2018) Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect 7(5):R196\u2013R211. https:\/\/doi.org\/10.1530\/EC-18-0079","journal-title":"Endocr Connect"},{"issue":"8","key":"2608_CR60","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S et al (2017) Pembrolizumab-Induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770\u20132780. https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2608_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12022-019-9579-2","volume":"30","author":"BA Imblum","year":"2019","unstructured":"Imblum BA, Baloch ZW, Fraker D, LiVolsi VA (2019) Pembrolizumab-Induced thyroiditis. Endocr Pathol 30(2):163\u2013167. https:\/\/doi.org\/10.1007\/s12022-019-9579-2","journal-title":"Endocr Pathol"},{"key":"2608_CR62","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1089\/thy.2020.0075","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB et al (2020) Immune checkpoint Inhibitor-Induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid 30:1440\u20131450. https:\/\/doi.org\/10.1089\/thy.2020.0075","journal-title":"Thyroid"},{"issue":"1","key":"2608_CR63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","volume":"5","author":"TE Angell","year":"2018","unstructured":"Angell TE, Min L, Wieczorek TJ, Hodi FS (2018) Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. Genes Dis 5(1):46\u201348. https:\/\/doi.org\/10.1016\/j.gendis.2017.11.002","journal-title":"Genes Dis"},{"issue":"696","key":"2608_CR64","doi-asserted-by":"publisher","first-page":"eadg0675","DOI":"10.1126\/scitranslmed.adg0675","volume":"15","author":"MG Lechner","year":"2023","unstructured":"Lechner MG, Zhou Z, Hoang AT, Huang N, Ortega J, Scott LN et al (2023) Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci Transl Med 15(696):eadg0675. https:\/\/doi.org\/10.1126\/scitranslmed.adg0675","journal-title":"Sci Transl Med"},{"key":"2608_CR65","doi-asserted-by":"publisher","unstructured":"Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M et al (2021) CD4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 13(593). https:\/\/doi.org\/10.1126\/scitranslmed.abb7495","DOI":"10.1126\/scitranslmed.abb7495"},{"key":"2608_CR66","doi-asserted-by":"publisher","unstructured":"Ippolito S, Di Dalmazi G, Pani F, Sabini E, Caturegli P (2021) Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model. Thyroid.31(12):1839-49. https:\/\/doi.org\/10.1089\/thy.2021.0165","DOI":"10.1089\/thy.2021.0165"},{"issue":"4","key":"2608_CR67","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4049\/jimmunol.2200244","volume":"209","author":"MG Lechner","year":"2022","unstructured":"Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M et al (2022) Inhibition of IL-17A protects against thyroid Immune-Related adverse events while preserving checkpoint inhibitor antitumor efficacy. J Immunol 209(4):696\u2013709. https:\/\/doi.org\/10.4049\/jimmunol.2200244","journal-title":"J Immunol"},{"issue":"11","key":"2608_CR68","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H et al (2018) Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109(11):3583\u20133590. https:\/\/doi.org\/10.1111\/cas.13800","journal-title":"Cancer Sci"},{"issue":"1","key":"2608_CR69","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","volume":"12","author":"Z Khan","year":"2021","unstructured":"Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V et al (2021) Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint Blockade. Nat Commun 12(1):3355. https:\/\/doi.org\/10.1038\/s41467-021-23661-4","journal-title":"Nat Commun"},{"issue":"2","key":"2608_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","volume":"68","author":"H Inaba","year":"2021","unstructured":"Inaba H, Ariyasu H, Iwakura H, Kurimoto C, Takeshima K, Morita S et al (2021) Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors. Endocr J 68(2):231\u2013241. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0371","journal-title":"Endocr J"},{"issue":"12","key":"2608_CR71","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1210\/jc.2009-1404","volume":"94","author":"AL Mitchell","year":"2009","unstructured":"Mitchell AL, Cordell HJ, Soemedi R, Owen K, Skinningsrud B, Wolff AB et al (2009) Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison\u2019s disease and graves\u2019 disease susceptibility. J Clin Endocrinol Metab 94(12):5139\u20135145. https:\/\/doi.org\/10.1210\/jc.2009-1404","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2608_CR72","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/js.2017-00432","volume":"2","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T et al (2018) Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. J Endocr Soc 2(3):241\u2013251. https:\/\/doi.org\/10.1210\/js.2017-00432","journal-title":"J Endocr Soc"},{"issue":"8","key":"2608_CR73","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1007\/s10238-023-01082-5","volume":"23","author":"A Nervo","year":"2023","unstructured":"Nervo A, Ferrari M, Gruosso G, Migliore E, Basile S, D\u2019Angelo V et al (2023) Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience. Clin Exp Med 23(8):4817\u20134824. https:\/\/doi.org\/10.1007\/s10238-023-01082-5","journal-title":"Clin Exp Med"},{"issue":"11","key":"2608_CR74","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","volume":"108","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Jiao X, Lai X (2023) Clinical characters and influence factors of immune checkpoint Inhibitor-related thyroid dysfunction. J Clin Endocrinol Metab 108(11):2916\u20132923. https:\/\/doi.org\/10.1210\/clinem\/dgad260","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2608_CR75","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.4049\/jimmunol.1200311","volume":"189","author":"AK Huber","year":"2012","unstructured":"Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E et al (2012) Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J Immunol 189(6):3043\u20133053. https:\/\/doi.org\/10.4049\/jimmunol.1200311","journal-title":"J Immunol"},{"key":"2608_CR76","doi-asserted-by":"publisher","unstructured":"Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB et al (2020) Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid.30(10):1440-50. https:\/\/doi.org\/10.1089\/thy.2020.0075","DOI":"10.1089\/thy.2020.0075"},{"issue":"1","key":"2608_CR77","doi-asserted-by":"publisher","first-page":"100868","DOI":"10.1016\/j.xcrm.2022.100868","volume":"4","author":"S Bukhari","year":"2023","unstructured":"Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y et al (2023) Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med 4(1):100868. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100868","journal-title":"Cell Rep Med"},{"issue":"7","key":"2608_CR78","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"I Yamauchi","year":"2017","unstructured":"Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M et al (2017) Clinical features of Nivolumab-Induced thyroiditis: A case series study. Thyroid 27(7):894\u2013901. https:\/\/doi.org\/10.1089\/thy.2016.0562","journal-title":"Thyroid"},{"key":"2608_CR79","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","volume":"103","author":"D \u00c1lvarez-Sierra","year":"2019","unstructured":"\u00c1lvarez-Sierra D, Mar\u00edn-S\u00e1nchez A, Ruiz-Bl\u00e1zquez P, de Jes\u00fas Gil C, Iglesias-Felip C, Gonz\u00e1lez \u00d3 et al (2019) Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 103:102285. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.013","journal-title":"J Autoimmun"},{"issue":"23","key":"2608_CR80","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.Can-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B et al (2016) Tumor-Intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian Cancer and melanoma. Cancer Res 76(23):6964\u20136974. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0258","journal-title":"Cancer Res"},{"issue":"8","key":"2608_CR81","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","volume":"20","author":"M Gato-Ca\u00f1as","year":"2017","unstructured":"Gato-Ca\u00f1as M, Zuazo M, Arasanz H, Iba\u00f1ez-Vea M, Lorenzo L, Fernandez-Hinojal G et al (2017) PDL1 signals through conserved sequence motifs to overcome Interferon-Mediated cytotoxicity. Cell Rep 20(8):1818\u20131829. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.075","journal-title":"Cell Rep"},{"issue":"6","key":"2608_CR82","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S et al (2019) PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell 74(6):1215\u201326e4. https:\/\/doi.org\/10.1016\/j.molcel.2019.04.005","journal-title":"Mol Cell"},{"issue":"1","key":"2608_CR83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41392-021-00463-0","volume":"6","author":"W Zhang","year":"2021","unstructured":"Zhang W, Jin J, Wang Y, Fang L, Min L, Wang X et al (2021) PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus. Signal Transduct Target Ther 6(1):81. https:\/\/doi.org\/10.1038\/s41392-021-00463-0","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2608_CR84","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2608_CR85","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.Ccr-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of Immune-Related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1136","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2608_CR86","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 44(2):117\u2013122. https:\/\/doi.org\/10.1111\/1346-8138.13520","journal-title":"J Dermatol"},{"issue":"4","key":"2608_CR87","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M et al (2023) Association of Immune-Related adverse events with efficacy of Atezolizumab in patients with Non-Small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol 9(4):527\u2013535. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7711","journal-title":"JAMA Oncol"},{"issue":"2","key":"2608_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5306\/wjco.v12.i2.103","volume":"12","author":"M Peravali","year":"2021","unstructured":"Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S et al (2021) Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 12(2):103\u2013114. https:\/\/doi.org\/10.5306\/wjco.v12.i2.103","journal-title":"World J Clin Oncol"},{"issue":"10","key":"2608_CR89","doi-asserted-by":"publisher","first-page":"e1742","DOI":"10.1002\/onco.13868","volume":"26","author":"DJ Martini","year":"2021","unstructured":"Martini DJ, Goyal S, Liu Y, Evans ST, Olsen TA, Case K et al (2021) Immune-Related adverse events as clinical biomarkers in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist 26(10):e1742\u2013e50. https:\/\/doi.org\/10.1002\/onco.13868","journal-title":"Oncologist"},{"key":"2608_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33609","author":"L Lu","year":"2021","unstructured":"Lu L, Xing K, Wei W, Ling Y, Li P, Li S et al (2021) Immune-related adverse events predict responses to PD-1 Blockade immunotherapy in hepatocellular carcinoma. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33609","journal-title":"Int J Cancer"},{"key":"2608_CR91","doi-asserted-by":"publisher","first-page":"1190001","DOI":"10.3389\/fphar.2023.1190001","volume":"14","author":"L Lin","year":"2023","unstructured":"Lin L, Liu Y, Chen C, Wei A, Li W (2023) Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis. Front Pharmacol 14:1190001. https:\/\/doi.org\/10.3389\/fphar.2023.1190001","journal-title":"Front Pharmacol"},{"key":"2608_CR92","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S et al (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2608_CR93","doi-asserted-by":"publisher","first-page":"bvab100","DOI":"10.1210\/jendso\/bvab100","volume":"5","author":"SI Al Ashi","year":"2021","unstructured":"Al Ashi SI, Thapa B, Flores M, Ahmed R, Rahim SEG, Amir M et al (2021) Endocrine toxicity and outcomes in patients with metastatic malignancies treated with immune checkpoint inhibitors. J Endocr Soc 5(8):bvab100. https:\/\/doi.org\/10.1210\/jendso\/bvab100","journal-title":"J Endocr Soc"},{"issue":"2","key":"2608_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B, Castro S, Victor M, Oliveira J et al (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70(2):299\u2013309. https:\/\/doi.org\/10.1007\/s00262-020-02664-y","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2608_CR95","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","volume":"71","author":"YM Cheung","year":"2022","unstructured":"Cheung YM, Wang W, McGregor B, Hamnvik OR (2022) Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 71(8):1795\u20131812. https:\/\/doi.org\/10.1007\/s00262-021-03128-7","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2608_CR96","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","volume":"32","author":"S Street","year":"2021","unstructured":"Street S, Chute D, Strohbehn I, Zhao S, Rengarajan M, Faje A et al (2021) The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann Oncol 32(8):1050\u20131051. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.357","journal-title":"Ann Oncol"},{"issue":"3","key":"2608_CR97","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","volume":"64","author":"I Peir\u00f3","year":"2019","unstructured":"Peir\u00f3 I, Palmero R, Iglesias P, D\u00edez JJ, Sim\u00f3-Servat A, Mar\u00edn JA et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64(3):605\u2013613. https:\/\/doi.org\/10.1007\/s12020-019-01871-7","journal-title":"Endocrine"},{"issue":"9","key":"2608_CR98","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.eprac.2021.01.017","volume":"27","author":"DTW Lui","year":"2021","unstructured":"Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY et al (2021) Thyroid immune-Related adverse events in patients with Cancer treated with anti-PD1\/anti-CTLA4 immune checkpoint inhibitor combination: clinical course and outcomes. Endocr Pract 27(9):886\u2013893. https:\/\/doi.org\/10.1016\/j.eprac.2021.01.017","journal-title":"Endocr Pract"},{"key":"2608_CR99","doi-asserted-by":"publisher","unstructured":"Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L et al (2021) Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers (Basel) 13(4). https:\/\/doi.org\/10.3390\/cancers13040860","DOI":"10.3390\/cancers13040860"},{"issue":"7","key":"2608_CR100","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","volume":"30","author":"EA Basak","year":"2020","unstructured":"Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM et al (2020) Overt thyroid dysfunction and Anti-Thyroid antibodies predict response to Anti-PD-1 immunotherapy in Cancer patients. Thyroid 30(7):966\u2013973. https:\/\/doi.org\/10.1089\/thy.2019.0726","journal-title":"Thyroid"},{"issue":"9","key":"2608_CR101","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00262-022-03151-2","volume":"71","author":"MS von Itzstein","year":"2022","unstructured":"von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S et al (2022) Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 71(9):2169\u20132181. https:\/\/doi.org\/10.1007\/s00262-022-03151-2","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2608_CR102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","volume":"22","author":"HS Baek","year":"2022","unstructured":"Baek HS, Jeong C, Shin K, Lee J, Suh H, Lim DJ et al (2022) Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr Disord 22(1):89. https:\/\/doi.org\/10.1186\/s12902-022-01004-8","journal-title":"BMC Endocr Disord"},{"issue":"21","key":"2608_CR103","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.Ccr-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ et al (2021) Early use of High-Dose glucocorticoid for the management of irae is associated with poorer survival in patients with advanced melanoma treated with Anti-PD-1 monotherapy. Clin Cancer Res 27(21):5993\u20136000. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1283","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2608_CR104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4158\/ep-2019-0244","volume":"26","author":"M Al Mushref","year":"2020","unstructured":"Al Mushref M, Guido PA, Collichio FA, Moore DT, Clemmons DR (2020) Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review. Endocr Pract 26(1):36\u201342. https:\/\/doi.org\/10.4158\/ep-2019-0244","journal-title":"Endocr Pract"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02608-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T20:02:29Z","timestamp":1756584149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02608-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":104,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02608-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YT declares that he is the owner of a patent and has submitted 3 additional patent disclosures; all patents mentioned are not related to the content of this manuscript. YT was previously (2015\u20132017) the PI on a basic research project jointly funded by the Juvenile Diabetes Research Foundation and Pfizer. The current manuscript is not related to that research project. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}